Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | ALB | P02768 | 3/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | CPA2 | P48052 | 2/20 | 0.35 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952207 | 0.87 | GNPAT (0.44) | CA2CTSSCTSKGNPAT | |
| SCHEMBL20952208 | 0.87 | GNPAT (0.44) | CA2CTSSCTSKGNPAT | |
| SCHEMBL20950960 | 0.77 | GRIA1 (0.45) | CTSSCTSKACACBGNPAT | |
| SCHEMBL20950958 | 0.77 | GRIA1 (0.45) | CTSSCTSKACACBGNPAT | |
| SCHEMBL20951504 | 0.76 | CTSS (0.46) | CA1CA2CTSSCTSKGNPAT | |
| SCHEMBL20951507 | 0.76 | CTSS (0.46) | CA1CA2CTSSCTSKGNPAT | |
| SCHEMBL20951608 | 0.74 | SIRT6 (0.48) | CA1CA2GNPATCPA1CPA2 | |
| SCHEMBL20951496 | 0.74 | SIRT6 (0.48) | CA1CA2GNPATCPA1CPA2 | |
| SCHEMBL20951495 | 0.74 | SIRT6 (0.48) | CA1CA2GNPATCPA1CPA2 | |
| SCHEMBL20950858 | 0.73 | ITGB1 (0.45) | CTSSCTSKGNPATKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | CA1 2790/4885CA2 2367/4885ALB 1312/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | CA1 2790/4885CA2 2367/4885ALB 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.